|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nasim F, Sabath BF and Eapen GA: Lung
cancer. Med Clin North Am. 103:463–473. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rodriguez-Canales J, Parra-Cuentas E and
Wistuba II: Diagnosis and molecular classification of lung cancer.
Cancer Treat Res. 170:25–46. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen W, Zheng R, Zeng H, Zhang S and He J:
Annual report on status of cancer in China, 2011. Chin J Cancer
Res. 27:2–12. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zou XN, Lin DM, Wan X, Chao A, Feng QF,
Dai Z, Yang GH and Lv N: Histological subtypes of lung cancer in
Chinese males from 2000 to 2012. Biomed Environ Sci. 27:3–9.
2014.PubMed/NCBI
|
|
6
|
Wang S, Liu F, Zhu J, Chen P, Liu H, Liu Q
and Han J: DNA repair genes ERCC1 and BRCA1 expression in non-small
cell lung cancer chemotherapy drug resistance. Med Sci Monit.
22:1999–2005. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Umihanic S, Umihanic S, Jamakosmanovic S,
Brkic S, Osmic M, Dedic S and Ramic N: Glasgow prognostic score in
patients receiving chemotherapy for non-small-cell lung cancer in
stages IIIb and IV. Med Arch. 68:83–85. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sun Y, Campisi J, Higano C, Beer TM,
Porter P, Coleman I, True L and Nelson PS: Treatment-induced damage
to the tumor microenvironment promotes prostate cancer therapy
resistance through WNT16B. Nat Med. 18:1359–1368. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li X, Lewis MT, Huang J, Gutierrez C,
Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC,
et al: Intrinsic resistance of tumorigenic breast cancer cells to
chemotherapy. J Natl Cancer Inst. 100:672–679. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Johnson DH, Schiller JH and Bunn PA Jr:
Recent clinical advances in lung cancer management. J Clin Oncol.
32:973–982. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Reck M, Heigener DF, Mok T, Soria JC and
Rabe KF: Management of non-small-cell lung cancer: Recent
developments. Lancet. 382:709–719. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kelman AD and Peresie HJ: Mode of DNA
binding of cis-platinum(II) antitumor drugs: A base
sequence-dependent mechanism is proposed. Cancer Treat Rep.
63:1445–1452. 1979.PubMed/NCBI
|
|
13
|
Giaccone G: Clinical perspectives on
platinum resistance. Drugs. 59 (Suppl 4):S9–S17, S37-S38. 2000.
View Article : Google Scholar
|
|
14
|
Momekov G, Ferdinandov D, Bakalova A,
Zaharieva M, Konstantinov S and Karaivanova M: In vitro
toxicological evaluation of a dinuclear platinum(II) complex with
acetate ligands. Arch Toxicol. 80:555–560. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Eljack ND, Ma HY, Drucker J, Shen C,
Hambley TW, New EJ, Friedrich T and Clarke RJ: Mechanisms of cell
uptake and toxicity of the anticancer drug cisplatin. Metallomics.
6:2126–2133. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tutar L, Özgür A and Tutar Y: Involvement
of miRNAs and pseudogenes in cancer. Methods Mol Biol. 1699:45–66.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tan S, Sun D, Pu W, Gou Q, Guo C, Gong Y,
Li J, Wei YQ, Liu L, Zhao Y and Peng Y: Circular RNA F-circEA-2a
derived from EML4-ALK fusion gene promotes cell migration and
invasion in non-small cell lung cancer. Mol Cancer. 17:1382018.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu KL, Tsai YM, Lien CT, Kuo PL and Hung
AJ: The roles of MicroRNA in lung cancer. Int J Mol Sci.
20:16112019. View Article : Google Scholar
|
|
20
|
Zhao WY, Wang Y, An ZJ, Shi CG, Zhu GA,
Wang B, Lu MY, Pan CK and Chen P: Downregulation of miR-497
promotes tumor growth and angiogenesis by targeting HDGF in
non-small cell lung cancer. Biochem Biophys Res Commun.
435:466–471. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Allen KE and Weiss GJ: Resistance may not
be futile: microRNA biomarkers for chemoresistance and potential
therapeutics. Mol Cancer Ther. 9:3126–3136. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ma Y, Li X, Cheng S, Wei W and Li Y:
MicroRNA-106a confers cisplatin resistance in non-small cell lung
cancer A549 cells by targeting adenosine triphosphatase-binding
cassette A1. Mol Med Rep. 11:625–632. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jiang X, Wu J, Zhang Y, Wang S, Yu X, Li R
and Huang X: MiR-613 functions as tumor suppressor in
hepatocellular carcinoma by targeting YWHAZ. Gene. 659:168–174.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Su X, Gao C, Feng X and Jiang M: miR-613
suppresses migration and invasion in esophageal squamous cell
carcinoma via the targeting of G6PD. Exp Ther Med. 19:3081–3089.
2020.PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li C, Zhao W, Pan X, Li X, Yan F, Liu S,
Feng J and Lu J: LncRNA KTN1-AS1 promotes the progression of
non-small cell lung cancer via sponging of miR-130a-5p and
activation of PDPK1. Oncogene. 39:6157–6171. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mengoli MC, Longo FR, Fraggetta F, Cavazza
A, Dubini A, Alì G, Guddo F, Gilioli E, Bogina G, Nannini N, et al:
The 2015 world health organization classification of lung tumors:
New entities since the 2004 classification. Pathologica. 110:39–67.
2018.PubMed/NCBI
|
|
28
|
Vasconcellos VF, Marta GN, da Silva EM,
Gois AF, de Castria TB and Riera R: Cisplatin versus carboplatin in
combination with third-generation drugs for advanced non-small cell
lung cancer. Cochrane Database Syst Rev. 1:CD0092562020.PubMed/NCBI
|
|
29
|
Rotolo F, Dunant A, Le Chevalier T, Pignon
JP and Arriagada R; IALT Collaborative Group, : Adjuvant
cisplatin-based chemotherapy in nonsmall-cell lung cancer: New
insights into the effect on failure type via a multistate approach.
Ann Oncol. 25:2162–2166. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hu J, Xu C, Cheng B, Jin L, Li J, Gong Y,
Lin W, Pan Z and Pan C: Imperatorin acts as a cisplatin sensitizer
via downregulating Mcl-1 expression in HCC chemotherapy. Tumour
Biol. 37:331–339. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang L, Shi ZM, Jiang CF, Liu X, Chen QD,
Qian X, Li DM, Ge X, Wang XF, Liu LZ, et al: MiR-143 acts as a
tumor suppressor by targeting N-RAS and enhances
temozolomide-induced apoptosis in glioma. Oncotarget. 5:5416–5427.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hong L, Han Y, Zhang Y, Zhang H, Zhao Q,
Wu K and Fan D: MicroRNA-21: A therapeutic target for reversing
drug resistance in cancer. Expert Opin Ther Targets. 17:1073–1080.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhao Z, Lv B, Zhang L, Zhao N and Lv Y:
miR-202 functions as a tumor suppressor in non-small cell lung
cancer by targeting STAT3. Mol Med Rep. 16:2281–2289. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shi ZM, Wang L, Shen H, Jiang CF, Ge X, Li
DM, Wen YY, Sun HR, Pan MH, Li W, et al: Downregulation of miR-218
contributes to epithelial-mesenchymal transition and tumor
metastasis in lung cancer by targeting Slug/ZEB2 signaling.
Oncogene. 36:2577–2588. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Dong Z, Zhong Z, Yang L, Wang S and Gong
Z: MicroRNA-31 inhibits cisplatin-induced apoptosis in non-small
cell lung cancer cells by regulating the drug transporter ABCB9.
Cancer Lett. 343:249–257. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ning FL, Wang F, Li ML, Yu ZS, Hao YZ and
Chen SS: MicroRNA-182 modulates chemosensitivity of human non-small
cell lung cancer to cisplatin by targeting PDCD4. Diagn Pathol.
9:1432014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li Y, Li L, Guan Y, Liu X, Meng Q and Guo
Q: MiR-92b regulates the cell growth, cisplatin chemosensitivity of
A549 non small cell lung cancer cell line and target PTEN. Biochem
Biophys Res Commun. 440:604–610. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Feng B, Wang R, Song HZ and Chen LB:
MicroRNA-200b reverses chemoresistance of docetaxel-resistant human
lung adenocarcinoma cells by targeting E2F3. Cancer. 118:3365–3376.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li B, Liu D, Yang P, Li HY and Wang D:
miR-613 inhibits liver cancer stem cell expansion by regulating
SOX9 pathway. Gene. 707:78–85. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Goodenough DA and Paul DL: Beyond the gap:
Functions of unpaired connexon channels. Nat Rev Mol Cell Biol.
4:285–294. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
James CC, Zeitz MJ, Calhoun PJ, Lamouille
S and Smyth JW: Altered translation initiation of Gja1 limits gap
junction formation during epithelial-mesenchymal transition. Mol
Biol Cell. 29:797–808. 2018. View Article : Google Scholar : PubMed/NCBI
|
